X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Asia

Generics Pharma Company, Normon Laboratories, Selects TraceLink to Comply with EU FMD Serialization Regulations

Yuvraj_pawp by Yuvraj_pawp
27th October 2017
in Asia, News

TraceLink Inc., the World’s Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes announced that Spanish-based pharmaceutical manufacturer, Normon Laboratories, has selected TraceLink’s serialization solutions to comply with the EU Falsified Medicines Directive (FMD) serialization requirements.

As the first generics pharmaceutical manufacturer in Spain, Normon Laboratories has grown to be one of the most innovative and versatile pharmaceutical manufacturers in the industry. With high volumes of pharmaceuticals shipped throughout Spain and exported across the rest of the world, and offering additional contract manufacturing capabilities for customers in other markets, the company needed a serialization solution that could accommodate its various roles in the pharmaceutical supply chain and ensure compliance for its customers, as well as its own product lines. Normon selected TraceLink for its ability to scale at the enterprise level and its seamless integration with multiple contract manufacturing organizations, in order to enable compliance with the EU FMD serialization regulations.

“At Normon, we uphold our commitment to developing the safest and highest quality medicines at affordable prices for everyone. Our dedication to ensuring patient safety was a key factor in selecting a partner with a proven solution to comply with EU FMD,” said Gonzalo Fernández Govantes, Chief Operating Officer of Normon Laboratories. “We selected TraceLink for its demonstrated EU and country compliance capabilities and enterprise scalability. As Normon continues to expand its business through ongoing innovation, we are confident that TraceLink can provide the breadth of support needed in order for Normon to successfully comply with EU and global regulations.”

“We are pleased to be working with Normon Laboratories, a pioneer in the development of generic medications, and one of the leading pharmaceutical companies in Spain. At TraceLink, we understand and value the need to institute an EU FMD compliance strategy that can scale quickly to accommodate for rapid growth and impending deadlines for serialization and individual country compliance,” said Shabbir Dahod, president and CEO of TraceLink. “Drug traceability and serialization is a global initiative and we look forward to working closely with Normon Laboratories to meet the approaching EU FMD deadline for serialization and ultimately, help secure the integrity of their products for patients across Europe.”

With track and trace regulations that vary country to country and the impending EU FMD deadline in February 2019, life sciences companies face unprecedented complexity, cost and risk in how they implement serialization strategies. TraceLink has already processed EU compliance reports for more than 660,000 units of product into the European hub 17 months ahead of deadline. The TraceLink European Union Compliance module supports traceability reporting requirements from a single platform, providing customers with a tested integration to the European hub for reporting information about their product master data, serialized product pack data, and status changes for products targeted for distribution across all Member States.

To learn more about meeting global pharmaceutical compliance deadlines and how to build a flexible serialization, track and trace, and reporting platform, please visit www.tracelink.com.

About TraceLink
TraceLink is the World’s Largest Track and Trace Network for connecting the Life Sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace. Leading businesses trust the TraceLink Life Sciences Cloud to deliver complete global connectivity, visibility and traceability of pharmaceuticals from ingredient to patient. A single point and click connection to the Life Sciences Cloud creates a supply chain control tower that delivers the information, insight and collaboration needed to improve performance and reduce risk across global supply, manufacturing and distribution operations. A winner of numerous industry awards including Deloitte’s Technology Fast 500 (ranked number 149 in 2016), the Amazon AWS Global Start-Up Challenge Grand Prize, and the Edison Award for Innovation in Health Management, the Life Sciences Cloud is used by businesses across the globe to meet strategic goals in ensuring global compliance, fighting drug counterfeiting, improving on-time and in-full delivery, protecting product quality and reducing operational cost. For more information on TraceLink and our solutions, visit www.tracelink.com

Tags: Middle East & South Asia
Previous Post

Irvine Scientific Will Now Offer Sunlight Medical Pipettes in the United States

Next Post

Eagle Pharmaceuticals Receives Tentative FDA Approval for PEMFEXY (Pemetrexed Injection) Ready-to-Dilute

Related Posts

FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace
Manufacturing

How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace

27th June 2022
Australia Creates A Novel Stem Cell Production Technique
Manufacturing

Australia Creates A Novel Stem Cell Production Technique

27th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis Promises $250M For Tropical Illnesses, Malaria

27th June 2022
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
Manufacturing

GSK Commits £1 Billion To Combat Infections In Poor Nations

27th June 2022
Next Post

Eagle Pharmaceuticals Receives Tentative FDA Approval for PEMFEXY (Pemetrexed Injection) Ready-to-Dilute

Latest News

FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace
Manufacturing

How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace

27th June 2022
Australia Creates A Novel Stem Cell Production Technique
Manufacturing

Australia Creates A Novel Stem Cell Production Technique

27th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis Promises $250M For Tropical Illnesses, Malaria

27th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In